These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24997558)

  • 1. Non-immune-based treatment for type 1 diabetes: the way to go?
    Rigby MR
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):681-2. PubMed ID: 24997558
    [No Abstract]   [Full Text] [Related]  

  • 2. Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration.
    Weir GC; Bonner-Weir S
    Endocrinology; 2010 Jul; 151(7):2971-3. PubMed ID: 20570953
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
    Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
    Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
    Zhao Y; Yang L; Wang X; Zhou Z
    Diabetes Metab Res Rev; 2014 Nov; 30(8):646-53. PubMed ID: 24446278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
    Zhao Y; Yang L; Xiang Y; Liu L; Huang G; Long Z; Li X; Leslie RD; Wang X; Zhou Z
    J Clin Endocrinol Metab; 2014 May; 99(5):E876-80. PubMed ID: 24432999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time for testing incretin therapies in early type 1 diabetes?
    Bosi E
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2607-9. PubMed ID: 20525907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.
    Xue S; Posgai A; Wasserfall C; Myhr C; Campbell-Thompson M; Mathews CE; Brusko T; Rabinovitch A; Savinov A; Battaglia M; Schatz D; Haller M; Atkinson MA
    Diabetes; 2015 Nov; 64(11):3873-84. PubMed ID: 26185279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
    Suarez-Pinzon WL; Rabinovitch A
    Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.
    Suarez-Pinzon WL; Cembrowski GS; Rabinovitch A
    Diabetologia; 2009 Aug; 52(8):1680-2. PubMed ID: 19455306
    [No Abstract]   [Full Text] [Related]  

  • 13. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 15. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
    Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
    J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.
    Jamaluddin JL; Huri HZ; Vethakkan SR; Mustafa N
    Pharmacogenomics; 2014 Feb; 15(2):235-49. PubMed ID: 24444412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck M; Smith U
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of monoclonal antibodies and DPP-IV inhibitors in the treatment of type 1 diabetes: a plausible treatment modality?
    Dubala A; Gupta A; Samanta MK
    Med Hypotheses; 2014 Jul; 83(1):1-5. PubMed ID: 24810674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.